drugset / Trial / NCT05833711
Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Froniglutide in Patients With Idiopathic Inflammatory Myopathy ("FROniGlutide Study")
Timeline
- Start
- 2023-09-05
- Primary completion
- 2025-03
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Froniglutide | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Subject | Froniglutide | Protein / enzyme biologic | 70 mg | Subcutaneous |